{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.4","upperLimit":"16.1","value":"8.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"}],"units":"Participants"}],"description":"Adverse events are graded using CTCAE v3.0. Grade refers to the severity of the AE. The CTCAE v3.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE.","dispersionType":"95% Confidence Interval","groups":[{"description":"Radiation therapy followed by surgery followed by, for patients with positive margins, radiation therapy boost","id":"OG000","title":"Cohort B - No Chemotherapy"}],"paramType":"NUMBER","populationDescription":"All eligible patients on Cohort B who started study treatment and had an assessment of toxicity at 2 years. (See limitations and caveats, Cohort A is not included.)","reportingStatus":"POSTED","timeFrame":"2 years after start of treatment (+/- 3 months)","title":"Late Radiation Morbidity Rate (≥ Grade 2 Lymphedema, Subcutaneous Fibrosis or Joint Stiffness) at 2 Years From the Start of Radiotherapy as Measured by CTCAE v3.0","type":"SECONDARY","unitOfMeasure":"percentage of participants"}